New combo therapy aims to wipe out rare bladder cancer before surgery

NCT ID NCT06091124

First seen Jan 07, 2026 · Last updated May 13, 2026 · Updated 18 times

Summary

This study tests whether giving a combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (etoposide and cisplatin) before bladder removal surgery can completely eliminate a rare and aggressive type of bladder cancer (neuroendocrine carcinoma). About 22 adults aged 18-75 with this cancer will receive up to 4 cycles of the drug combo, then have their bladder removed. The main goal is to see how many patients have no cancer left in the removed bladder, and to check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Jiangsu Province Hospital

    RECRUITING

    Nanjing, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • RenJi Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200127, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Xi'an Jiao Tong University

    RECRUITING

    Xi'an, Shaanxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Second Hospital of Tianjin Medical University

    RECRUITING

    Tianjin, Tianjin Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • West China Hospital

    RECRUITING

    Chengdu, Sichuan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.